Patents by Inventor Ying Kai Chan

Ying Kai Chan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for inhibiting viral vector-induced inflammatory responses
    Patent number: 11981911
    Abstract: Provided herein, in some embodiments, are recombinant viral genomes comprising an inhibitory oligonucleotide that reduces inflammation for use, for example, in gene therapy.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: May 14, 2024
    Assignee: President and Fellows of Harvard College
    Inventors: Ying Kai Chan, George M. Church
  • ENGINEERED VIRAL VECTOR REDUCES INDUCTION OF INFLAMMATORY AND IMMUNE RESPONSES
    Publication number: 20240043849
    Abstract: Modified viral genomes are able to reduce induction of inflammatory and immune antiviral responses. This manifests itself in reduced NF-kB activity, increased viral transduction rates, and increased expression of transgenes. Viral genomes are modified by incorporating one or more oligonucleotide sequences which are able to bind to TLR9 but not induce activation of it. The oligonucleotide sequences may be synthetic, bacterial, human, or from any other source.
    Type: Application
    Filed: June 9, 2023
    Publication date: February 8, 2024
    Applicant: President and Fellows of Harvard College
    Inventors: Ying Kai Chan, George M. Church
  • COMPOSITIONS AND METHODS FOR INHIBITING NUCLEIC ACID VECTOR-INDUCED INFLAMMATORY RESPONSES
    Publication number: 20220259599
    Abstract: Provided herein, in some embodiments, are nucleic acid vectors, such as recombinant viral genomes, comprising an inhibitory oligonucleotide that reduces inflammation for use, for example, in gene therapy.
    Type: Application
    Filed: May 14, 2020
    Publication date: August 18, 2022
    Applicant: President and Fellows of Harvard College
    Inventors: Ying Kai Chan, Jessica Chiang, George M. Church
  • Engineered viral vector reduces induction of inflammatory and immune responses
    Patent number: 11339396
    Abstract: Modified viral genomes are able to reduce induction of inflammatory and immune anti-viral responses. This manifests itself in reduced NF-kB activity, increased viral transduction rates, and increased expression of transgenes. Viral genomes are modified by incorporating one or more oligonucleotide sequences which are able to bind to TLR9 but not induce activation of it. The oligonucleotide sequences may be synthetic, bacterial, human, or from any other source.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: May 24, 2022
    Assignee: President and Fellows of Harvard College
    Inventors: Ying Kai Chan, George M. Church
  • COMPOSITIONS AND METHODS FOR INHIBITING VIRAL VECTOR-INDUCED INFLAMMATORY RESPONSES
    Publication number: 20200270637
    Abstract: Provided herein, in some embodiments, are recombinant viral genomes comprising an inhibitory oligonucleotide that reduces inflammation for use, for example, in gene therapy.
    Type: Application
    Filed: November 8, 2018
    Publication date: August 27, 2020
    Applicant: President and Fellows of Harvard College
    Inventors: Ying Kai Chan, George M. Church
  • Enhanced immunogenicity of mRNA with co-encoded adjuvant sequences
    Patent number: 10736957
    Abstract: Described herein are in vitro-transcribed (IVT) RNA molecules comprising, a 5? cap structure, a coding region encoding an antigen polypeptide, an immunostimulatory RNA sequence, and a poly(A) tail.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: August 11, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Ying Kai Chan, Jessica Jing-Shiuan Chiang
  • ENGINEERED VIRAL VECTOR REDUCES INDUCTION OF INFLAMMATORY AND IMMUNE RESPONSES
    Publication number: 20190316151
    Abstract: Modified viral genomes are able to reduce induction of inflammatory and immune anti-viral responses. This manifests itself in reduced NF-kB activity, increased viral transduction rates, and increased expression of transgenes. Viral genomes are modified by incorporating one or more oligonucleotide sequences which are able to bind to TLR9 but not induce activation of it. The oligonucleotide sequences may be synthetic, bacterial, human, or from any other source.
    Type: Application
    Filed: October 23, 2018
    Publication date: October 17, 2019
    Applicant: President and Fellows of Harvard College
    Inventors: Ying Kai Chan, George Church
  • ENHANCED IMMUNOGENICITY OF mRNA WITH CO-ENCODED ADJUVANT SEQUENCES
    Publication number: 20190184006
    Abstract: Described herein are in vitro-transcribed (IVT) RNA molecules comprising, a 5? cap structure, a coding region encoding an antigen polypeptide, an immunostimulatory RNA sequence, and a poly(A) tail.
    Type: Application
    Filed: October 4, 2018
    Publication date: June 20, 2019
    Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Ying Kai Chan, Jessica Jing-Shiuan Chiang, George M. Church
  • ENGINEERED VIRAL VECTOR REDUCES INDUCTION OF INFLAMMATORY AND IMMUNE RESPONSES
    Publication number: 20190177731
    Abstract: Modified viral genomes are able to reduce induction of inflammatory and immune anti-viral responses. This manifests itself in reduced NF-kB activity, increased viral transduction rates, and increased expression of transgenes. Viral genomes are modified by incorporating one or more oligonucleotide sequences which are able to bind to TLR9 but not induce activation of it. The oligonucleotide sequences may be synthetic, bacterial, human, or from any other source.
    Type: Application
    Filed: June 8, 2017
    Publication date: June 13, 2019
    Applicant: Presicent and Fellows Harvard College
    Inventors: Ying Kai Chan, George M. Church